Newsletter SignupSearch

EQIPD Webinar Series 2023

EQIPD (Enhancing Quality in Preclinical Data) develops solutions that facilitate improvements in data quality without impacting innovation and freedom of research, developed by scientists in academia and industry.

To support best practices and improvements in preclinical data quality, Cohen Veterans Bioscience (CVB) is a guarantor of EQIPD, and we’re excited to be a part of EQIPD’s 2023 Webinar Series featuring presentations by experts in preclinical and translational research.

Running through June 21st, the series kicks off on March 1st with the webinar “Evidence, origins and impact of lacking rigour in research” with Dr. Thomas Steckler of Janssen Pharmaceuticals and Professor Malcolm Macleod of the University of Edinburgh.

View the webinar schedule and topics below and register to attend.

For more information, visit the EQIPD website.

EQIPD 2023 Webinar Series Schedule

Date Name Organization Topic
March 1, 2023 Prof. Malcolm Macleod / Dr. Thomas Steckler University of Edinburgh, Edinburgh, UK / Janssen, Beerse, Belgium Evidence, origins and impact of lacking rigour in research
March 15, 2023 Dr. Kim Wever Radboud university medical center, Nijmegen, The Netherlands Systematic review and meta-analysis of animal studies
March 29, 2023 Dr. René Bernard QUEST Centre, Charité, Berlin, Germany Exploratory versus confirmatory research
April 12, 2023 Prof. Martin Michel University of Mainz, Mainz, Germany A hitchhiker’s guide to experimental design and statistics
April 26, 2023 Dr. Jan Vollert Imperial College, London, UK The EQIPD framework for research rigour
May 10, 2023 Dr. Magali Haas Cohen Veterans Bioscience Criteria for translational validity
May 24, 2023 Dr. Rita Balice-Gordon Muna Therpeutics Industry perspective on using tools like EQIPD
June 7, 2023 Dr. Björn Gerlach / Anton Bespalov PAASP GmbH The EQIPD quality system and auditing
June 21, 2023 Martien Kas / TBD University of Groningen / Biotech Use cases

Learn More

Watch Webinar

Magali Haas, MD, PhD
CEO & President, Cohen Veterans Bioscience

Dr. Haas is founder of Cohen Veterans Bioscience (CVB), a global organization that leads pioneering efforts in PTSD and TBI research, including clinical trials, biotechnology, genetics, and biomarker discovery. She has more than 15 years of pharmaceutical leadership experience in neuroscience clinical development, translational medicine, and diagnostics, primarily at J&J. Dr. Haas has spearheaded the Brain Trauma Blueprint initiative to establish a national roadmap for PTSD & TBI precision therapeutics research.

More Webinars

Pathway and Network Based Discovery of Gene Signatures
ALS Patients Being PRO-ACTive: Can ALS Big Data Bring the Next ALS Breakthrough
Collaborative bottom-up modeling in computational biomedicine
Cohen Veterans Bioscience - Advancing Brain Health

Get the latest updates in TBI and PTSD research

Sign up for our newsletter to learn how we’re advancing solutions for brain trauma.

This field is for validation purposes and should be left unchanged.